Calidi Biotherapeutics (CLDI) Profit After Tax (2022 - 2025)

Calidi Biotherapeutics has reported Profit After Tax for 4 years, with the latest figure at -$4.2 million in Q4 2025.

• For the quarter ending Q4 2025, Profit After Tax fell 3.21% year-over-year to -$4.2 million; the trailing twelve-month figure through Dec 2025 stood at -$20.2 million (up 8.78% YoY), and the FY2025 full-year result was -$20.1 million, up 9.39% from the prior year.
• Profit After Tax for Q4 2025 stood at -$4.2 million, up from -$5.1 million in the prior quarter.
• The five-year high for Profit After Tax was -$2.0 million in Q3 2023, with the low at -$12.5 million in Q2 2023.
• Average Profit After Tax over 4 years is -$6.1 million, with a median of -$5.6 million recorded in 2022.
• Peak annual rise in Profit After Tax reached 62.2% in 2023, while the deepest fall reached 173.19% in 2023.
• Tracing CLDI's Profit After Tax over 4 years: stood at -$7.8 million in 2022, then decreased by 6.1% to -$8.2 million in 2023, then soared by 50.39% to -$4.1 million in 2024, then slipped by 3.21% to -$4.2 million in 2025.
• The last three Profit After Tax figures came in at -$4.2 million (Q4 2025), -$5.1 million (Q3 2025), and -$5.8 million (Q2 2025), per Business Quant data.

Peer Comparison